Pancreatic and extrapancreatic effects of GLP-1

Diabetes and Metabolism

Volumn 28, Issue 6 II, 2002, Pages

  Valverde, I ^a   Villanueva Penacarrillo M L ^a   Malaisse, W J ^b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Diabetes; GLP 1; Insulinotropic agents

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN;

ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; RAT; SECOND MESSENGER; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; PANCREAS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 12244266477     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. Montrose-Rafizadeh C, Egan JM, Roth J. Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action. Endocrinology, 1994, 135, 589-594.
2. Gutniak M, Ørskov C, Holst JJ, Ahren B, Effendic S. Antidiabetogenic effects of glucagon-like peptide-1(7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med, 1992, 326, 1316-1322.
3. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JV. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest, 1994, 93, 2263-2266.
4. D'Alessio DA, Prigeon RL, Ensinck JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide 1. Diabetes, 1995, 44, 1433-1437.
5. Nauck MA. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta Diabetol, 1998, 35, 117-129.
6. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated new-born rats resulting in persistently improved glucose homeostasis at adult age. Diabetes, 2001, 50, 1562-1570.
7. Morales M, López-Delgado MI, Alcántara, A, et al. Preserved effects upon glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes, 1997, 46, 1264-1269.
8. Malaisse WJ. The beta cell in NIDDM: giving light to the blind. Diabetologia, 1994, 37, S36-S42.
9. Leclercq-Meyer V, Malaisse WJ. Potentiation of glucagon-like peptide 1 insulinotropic action by succinic acid dimethyl ester. Life Sci, 1996, 58, 1195-1199.
10. Leclercq-Meyer V, Malaisse WJ. Potentiation of GLP-1 insulinotropic action by a nonglucidic nutrient in the pancreas of diabetic GK rats. Biochem Mol Med, 1996, 59, 87-90.
11. Zhang TM, Ladrière L, García-Martínez JA, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ. Effect of succinic acid dimethyl ester on GLP-1 secretion and insulinotropic action of glucagon-like peptide 1. Med Sci Res, 1996, 24, 349-350.
12. García-Martínez JA, Cancelas J, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ. Potentiation of the insulinotropic action of GLP-1 by succinic acid dimethyl ester in fed anaesthetised rats. Horm Metab Res, 2000, 32, 306-309.
13. García-Martínez JA, Cancelas J, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ. Prolongation of the insulinotropic action of glucagon-like peptide 1 by the dimethyl ester of succinic acid in an animal model of type-2 diabetes. Int J Mol Med, 2000, 6, 319-321.
14. Cancelas J, Villanueva-Peñacarrillo MI, Valverde I, Malaisse WJ. Synergistic insulinotropic effects of succinic acid dimethyl ester and exendin-4 in anaesthetized rats. Int J Mol Med, 2001, 8, 269-271.
15. Cancelas J, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ. Suppression by exendin(9-39)amide of glucagon-like peptide 1 insulinotropic action in rats infused with the dimethyl ester of succinic acid. Endocrine, 2001, 15, 283-285.
16. Cancelas J, García-Martínez JA, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ. Resistance of succinic acid dimethyl ester insulinotropic action to exendin(9-39)amide. Horm Metab Res, 2002, 34, 13-15.
17. Valverde I, Cancelas J, Villanueva-Peñacarrillo ML, Malaisse WJ. Potentiation by methyl pyruvate of GLP-1 insulinotropic action in normal rats. Int J Mol Med, 2001, 7, 621-623.
18. Cancelas J, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ. Potentiation by glutamic acid dimethyl ester of GLP-1 insulinotropic action in fed anaesthetized rats. Int J Mol Med, 2001, 8, 531-532.
19. Cancelas J, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ. Potentiation and or prolongation of glucagon-like peptide 1 insulinotropic action by either methyl pyruvate or the dimethyl ester of L-glutamic acid in an animal model of type-2 diabetes. Endocrine, 2001, 16, 113-116.
20. Cancelas J, García-Martínez JA, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ. Synergistic insulinotropic action of D-glucose pentaacetate and GLP-1 in rats. Med Sci Res, 1999, 27, 853-856.
21. García-Martínez JA, Ladrière L, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ. Insulinotropic action of α-D-glucose pentaacetate in vivo. Diab Nutr Metab, 1997, 10, 198-202.
22. Valverde I, Morales M, Clemente F, et al. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett, 1994, 349, 313-316.
23. Villanueva-Peñacarrillo ML, Alcántara AI, Clemente F, Delgado E, Valverde I. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia, 1994, 37, 1163-1166.
24. Ruiz-Grande C, Alarcón C, Mérida E, Valverde I. Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides, 1992, 13, 13-16.
25. Perea A, Viñambres C, Clemente F, Villanueva-Peñacarrillo ML, Valverde I. GLP-1(7-36)amide effects on glucose transport and metabolism in rat adipose tissue. Horm Metab Res, 1997, 29, 417-421.
26. Yang H, Egan JM, Wang Y, et al. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Amer J Physiol, 1998, 275, C675-C683.
27. Oben J, Morgan L, Fletcher J, Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol, 1991, 130, 267-272.
28. Miki H, Namba M, Nishimura T, et al. Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes, Biochim Biophys Acta, 1996, 1312, 132-136.
29. Egan JM, Montrose-Rafizadeh C, Wang YH, Bernier M, Roth J. Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-LI adipocytes: One of several potential extrapancreatic sites of GLP-1 action. Endocrinology, 1994, 135, 2070-2075.
30. O'Harte FP, Gray AM, Abdel-Wahab YH, Flatt PR. Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscle. Peptides, 1997, 18, 1327-1333.
31. Villanueva-Peñacarrillo ML, Márquez L, González N, Díaz-Miguel M, Valverde I. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res, 2001, 33, 73-77.
32. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Nat Acad Sci USA, 1992, 89, 8641-8645.
33. Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose MH, Adams LG. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-LI adipocytes. J Cell Physiol, 1997, 172, 275-283.
34. Valverde I, Mérida E, Delgado E, Trapote MA, Villanueva-Peñacarrillo ML. Presence and characterization of glucagon-like peptide-1(7-36)amide receptors in solubilized membranes of rat adipose tissue. Endocrinology, 1993, 132, 75-79.
35. Mérida E, Delgado E, Molina LM, Villanueva-Peñacarrillo ML, Valverde I. Presence of glucagon and glucagon-like peptide-1(7-36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab, 1993, 77, 1654-1657.
36. González N, Luque MA, Acitores A, Villanueva-Peñacarrillo ML, Valverde I. GLP-1 in human skeletal muscle: characteristics of action. Diabetologia, 2000, 43, A147, 570.
37. Delgado E, Luque MA, Alcántara A, et al. Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides, 1995, 16, 225-229.
38. Villanueva-Peñacarrillo ML, Delgado E, Vicent D, Mérida E, Alcántara AI, Valverde I. GLP-1(7-36)amide binding in skeletal muscle membranes from streptozotocin diabetic rats. Endocrine, 1995, 3, 685-687.
39. Alcántara AI, Morales M, Delgado E, et al. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys, 1997, 341, 1-7.
40. Villanueva-Peñacarrillo ML, Delgado E, Trapote MA, et al. Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol, 1995, 146, 183-189.
41. Luque MA, Márquez L, Valverde I, Villanueva-Peñacarrillo ML. A possible mediator in the glycogenic effect of GLP-1 in human skeletal muscle. Diabetologia, 1998, 41, A19-68.
42. Galera C, Clemente F, Alcántara A, et al. Inositolphosphoglycans and diacylglycerol are possible mediators in the GLP-1(7-36)amide glycogenic effect in BC3H-1 myocytes. Cell Biochem Funct, 1996, 14, 43-48.
43. Trapote MA, Clemente F, Galera C, et al. Inositolphosphoglycans implicated in the GLP-1(7-36)amide action in the liver. J Endocrinol Invest, 1996, 19, 114-118.
44. Márquez L, Trapote MA, Luque MA, Alcántara AI, Valverde I, Villanueva-Peñacarrillo ML. Inositolphosphoglycans possibly mediate the GLP-1 effects on rat liver and adipose tissue. Cell Biochem Funct, 1998, 16, 51-56.
45. Shalev A, Ninnis R, Keller U. Effects of glucagon-like peptide 1 (7-36)amide on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Horm Res, 1998, 49, 221-225.
46. Sandhu H, Wiesenthal SR, MacDonald PE, et al. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes, 1999, 48, 1045-1053.
47. Mizuno A, Kuwajima M, Ishida K, et al. Extrapancreatic action of truncated glucagon-like peptide-1 in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus. Metabolism, 1997, 46, 745-749.
48. Toft-Nielson M, Madsbad S, Holst JJ. The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes, 1996, 45, 552-556.
49. Orskov L, Holst JJ, Moller J, et al. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia, 1996, 39, 1227-1232.
50. Larsson H, Holst JJ, Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand, 1997, 160, 413-422.
51. Ryan AS, Egan JM, Habener JF, Elahi D. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab, 1998, 83, 2399-2404.
52. Ahren B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 I on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1997, 82, 473-478.
53. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes, 2000, 49, 611-617.
54. Freyse EJ, Knospe S, Becher T, El Hag O, Goke B, Fischer U. Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. Metabolism, 1999, 48, 134-137.
55. Vella A, Shah P, Basu R, et al. Effect of glucagon-like peptide- 1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes. Diabetes, 2001, 50, 565-572.